The phase III SEQUOIA trial compared first-line zanubrutinib vs bendamustine plus rituximab in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Findings from an interim analysis of the study were published in The Lancet Oncology.
